Elena Hartmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8202714/publications.pdf

Version: 2024-02-01

28 papers	658 citations	1040056 9 h-index	839539 18 g-index
30 all docs	30 docs citations	30 times ranked	1277 citing authors

#	Article	IF	Citations
1	9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. British Journal of Haematology, 2022, 196, 116-126.	2.5	9
2	Cutaneous epithelioid haemangiomas show somatic mutations in the mitogenâ€activated protein kinase pathway. British Journal of Dermatology, 2022, 186, 553-563.	1.5	3
3	<scp>Epsteinâ€Barrâ€Virus</scp> infection patterns in nodular lymphocyte predominant Hodgkinâ€lymphoma. Histopathology, 2022, , .	2.9	6
4	Acute systemic knockdown of Atg7 is lethal and causes pancreatic destruction in shRNA transgenic mice. Autophagy, 2022, 18, 2880-2893.	9.1	3
5	Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns. Annals of Hematology, 2021, 100, 1537-1546.	1.8	7
6	A large retroperitoneal lipoblastoma as an incidental finding: a case report. BMC Pediatrics, 2021, 21, 159.	1.7	5
7	Pilot study on the value of Raman spectroscopy in the entity assignment of salivary gland tumors. PLoS ONE, 2021, 16, e0257470.	2.5	3
8	The histological and molecular spectrum of lipoblastoma: A case series with identification of three novel gene fusions by targeted RNA-sequencing. Pathology Research and Practice, 2021, 226, 153591.	2.3	4
9	In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkinâ€™s lymphoma and facilitates ultrasensitive residual disease detection. Med, 2021, 2, 1171-1193.e11.	4.4	24
10	Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood, 2020, 136, 2851-2863.	1.4	47
11	Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Science Translational Medicine, 2019, 11, .	12.4	51
12	Identification of <scp> Candida albicans </scp> regulatory genes governing mucosal infection. Cellular Microbiology, 2018, 20, e12841.	2.1	23
13	Fusion of freehand SPECT and ultrasound: First experience in preoperative localization of sentinel lymph nodes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2304-2312.	6.4	28
14	The G protein-coupled estrogen receptor 1 (GPER-1) contributes to the proliferation and survival of mantle cell lymphoma cells. Haematologica, 2015, 100, e458-e461.	3.5	13
15	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2014, 15, 1090-1099.	10.7	315
16	Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab. Blood, 2013, 122, 1631-1631.	1.4	0
17	Proteasome Inhibition Leads to Dephosphorylation and Downregulation of Protein Expression of Members of the Akt/mTOR Pathway In MCL. Blood, 2010, 116, 4449-4449.	1.4	0
18	Enzastaurin Treatment Affects Multiple Regulatory Pathways at Transcriptome and Cellular Proteome Level of Mantle Cell Lymphoma. Blood, 2010, 116, 2893-2893.	1.4	0

#	Article	IF	Citations
19	Stroma-Induced TCL1 Expression In Chronic Lymphocytic Leukemia Cells Is Associated with Down Regulation of TCL1A-Targeting miRNAs. Blood, 2010, 116, 52-52.	1.4	0
20	RNA-Expression and Proteome Analysis Identify Complementary but Not Identical Molecular Targets in Enzastaurin-Treated Mantle Cell Lymphoma.. Blood, 2009, 114, 1915-1915.	1.4	0
21	Synergistic Antilymphoma Effect of Protein Kinase C Beta (PKCÎ²) and mTOR Inhibition in Mantle Cell Lymphoma.. Blood, 2009, 114, 4780-4780.	1.4	0
22	Marrow Stromal Cells Induce TCL1 Expression in Chronic Lymphocytic Leukemia B Cells.. Blood, 2009, 114, 2347-2347.	1.4	0
23	CCL3 and CCL4 Plasma Levels Correlate with Established Prognostic Markers in Chronic Lymphocytic Leukemia: Towards a Simple, ELISA-Based Assay for Risk Assessment.. Blood, 2009, 114, 358-358.	1.4	1
24	Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Clinical Oncology, 2008, 26, 4966-4972.	1.6	101
25	Spectral Karyotyping and SNP Microarray Analysis Define Uniparental Disomy (UPD) as a Novel Mutational Mechanism in MSI- and CSI-Colorectal Cancers. Analytical Cellular Pathology, 2008, 30, 507-507.	1.4	0
26	High-Level Expression of the T Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Co-Cultures and in Response to BCR Stimulation.. Blood, 2007, 110, 342-342.	1.4	0
27	Altered Cellular Protein Levels of Tumor Suppressor Genes and Heat Shock Elements (TRAP1) Indicate Sensitivity to the Proteasome Inhibitor Bortezomib (VelcadeÂ®) in Mantle Cell Lymphoma.. Blood, 2005, 106, 2424-2424.	1.4	14
28	Gene expression profiling in lymphoid malignancies. , 2001, , 162-186.		0